Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review

Individuals who carry an inherited mutation in the breast cancer 1 (BRCA1) and BRCA2 genes have a significant risk of developing breast and ovarian cancer over the course of their lifetime. As a result, there are important considerations for the clinician in the counseling, followup and management of mutation carriers. This review outlines salient aspects in the approach to patients at high risk of developing breast and ovarian cancer, including criteria for genetic testing, screening guidelines, surgical prophylaxis, and chemoprevention.

• Publication year

  2011

• Venue

  International Journal of Surgical Oncology

• Publication date

  2011-08-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2011/374012PMID 22312502PMCID 3263675
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Breast cancer—facts and figures

  2013cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

  2011cited by this paper
• Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.

  2011cited by this paper
• Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.

  2011cited by this paper
• Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.

  2011cited by this paper
• Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?

  2011cited by this paper
• Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.

  2011cited by this paper
• Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.

  2010cited by this paper
• Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.

  2010cited by this paper
• The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer

  2010cited by this paper
• Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

  2010cited by this paper
• Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age

  2010cited by this paper
• BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  2010cited by this paper
• Cancer facts and figures

  2010cited by this paper
• BRCA testing of breast cancer patients: medical specialists' referral patterns, knowledge and attitudes to genetic testing.

  2010cited by this paper
• Genetic/familial high-risk assessment: breast and ovarian.

  2010cited by this paper
• Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.

  2010cited by this paper
• Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features

  2010cited by this paper
• Contralateral Prophylactic Mastectomy is Associated with a Survival Advantage in High-Risk Women with a Personal History of Breast Cancer

  2010cited by this paper
• Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women

  2010cited by this paper
• Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study

  2010cited by this paper
• BRCA1 mutations and colorectal cancer in Poland

  2010cited by this paper
• Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis

  2010cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers

  2009cited by this paper
• Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing

  2009cited by this paper
• Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?

  2009cited by this paper
• The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer

  2009cited by this paper
• High Rates of Occult Fallopian Tube Cancer Diagnosed at Prophylactic Bilateral Salpingo-Oophorectomy

  2009cited by this paper
• Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer

  2009cited by this paper
• Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.

  2009cited by this paper
• Hereditary breast and ovarian cancer syndrome.

  2009cited by this paper
• Hereditary breast and ovarian cancer syndrome : the impact of race on uptake of genetic counseling and testing.

  2009cited by this paper
• The Fallopian Tube: Primary Site of Most Pelvic High-grade Serous Carcinomas

  2009cited by this paper
• Uptake, Time Course, and Predictors of Risk-Reducing Surgeries in BRCA Carriers

  2009cited by this paper
• Cost-effectiveness of testing for breast cancer susceptibility genes.

  2009cited by this paper
• BRCA in breast cancer: ESMO clinical recommendations.

  2009influential reference
• Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer.

  2008cited by this paper
• Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers

  2008cited by this paper
• Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.

  2008cited by this paper
• Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.

  2008cited by this paper
• Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers

  2008cited by this paper
• International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers

  2008cited by this paper
• Prevalence of pre-malignant and malignant lesions in prophylactic mastectomy specimens of BRCA1 mutation carriers: comparison with a control group

  2008cited by this paper
• BRCA1 mutations and prostate cancer in Poland

  2008cited by this paper
• Common variants of DNA repair genes and malignant melanoma.

  2008cited by this paper
• DNA repair pathways as targets for cancer therapy

  2008cited by this paper
• Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

  2008cited by this paper
• Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations

  2007cited by this paper
• Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high‐risk and population risk women is ineffective

  2007cited by this paper
• BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.

  2007cited by this paper
• Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.

  2007cited by this paper
• Development of an ovarian cancer symptom index

  2007cited by this paper
• Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.

  2007cited by this paper
• Development of an ovarian cancer symptom index: possibilities for earlier detection.

  2007cited by this paper
• Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer: Recommendations of the National Society of Genetic Counselors

  2007cited by this paper
• A systematic review of the effectiveness of magnetic resonance imaging ( MRI ) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer

  2007cited by this paper
• The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study.

  2007cited by this paper
• Development of an ovarian cancer symptom index: Possibilities for earlier detection

  2007cited by this paper
• A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer.

  2007cited by this paper
• Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series.

  2007cited by this paper
• Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups.

  2007cited by this paper
• BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy

  2007cited by this paper
• MRI in the Early Detection of Breast Cancer in Women with High Genetic Risk

  2006cited by this paper
• Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.

  2006cited by this paper
• Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

  2006cited by this paper
• Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer

  2006cited by this paper
• Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.

  2006cited by this paper
• Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.

  2006cited by this paper
• Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update

  2006cited by this paper
• Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

  2006cited by this paper
• Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

  2005cited by this paper
• Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: Public health implications

  2005cited by this paper
• Familial breast cancer: characteristics and outcome of BRCA 1–2 positive and negative cases

  2005influential reference
• BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study

  2005cited by this paper
• BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

  2005cited by this paper
• Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation Statement

  2005cited by this paper
• Early detection of breast and ovarian cancer in families with BRCA mutations.

  2005cited by this paper
• Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation Statement

  2005cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study

  2004cited by this paper
• BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews

  2004cited by this paper
• Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

  2004cited by this paper
• Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

  2004cited by this paper
• Loss of heterozygosity (LOH) in ovarian cancer

  2004cited by this paper
• BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.

  2004cited by this paper
• Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

  2003cited by this paper
• Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2

  2003cited by this paper
• Prognostic significance of BRCA1 expression in sporadic breast carcinomas

  2003cited by this paper
• Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations

  2002cited by this paper
• Cancer Incidence in BRCA1 mutation carriers.

  2002cited by this paper
• Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.

  2002cited by this paper
• Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population

  2002cited by this paper
• Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

  2002cited by this paper
• Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

  2001cited by this paper
• Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.

  2001cited by this paper
• BRCA2 is required for homology-directed repair of chromosomal breaks.

  2001cited by this paper
• Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas

  2001cited by this paper
• Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.

  2001cited by this paper

• Screening for Hereditary Cancer Syndromes

  2026cites this paper
• Mutation of BRCA1/2 Gene in Premenopausal Triple-Negative Breast Cancer Patients in West Sumatera

  2025cites this paper
• The BRCA mutation spectrum among breast and ovarian cancers in India: highlighting the need to screen BRCA1 185delAG among South Indians

  2024cites this paper
• VNTR Polymorphism in the Intron 5 of SIRT3 and Susceptibility to Breast Cancer

  2023cites this paper
• Chinese expert consensus on clinical practice of female fertility preservation

  2022cites this paper
• Evaluation of BRCA1/2 gene mutations in patients with high-risk breast and/or ovarian cancer in Turkey

  2022cites this paper
• Role of Genetic Polymorphisms in Breast Cancer

  2021cites this paper
• Managing a woman with BRCA mutations? Shared decision-making is key.

  2020cites this paper
• Characterization of environmental and genetic factors in multiple-case lymphoid cancer families

  2020cites this paper
• The Role of Stroma in Ovarian Cancer

  2020cites this paper
• The NCCN Criterion “Young Age at Onset” Alone is Not an Indicator of Hereditary Breast Cancer in Iranian Population

  2019cites this paper
• A high‐grade renal cell carcinoma with Somatic BRCA2 mutation

  2019cites this paper
• Negative regulation of BRCA1 by transforming acidic coiled-coil protein 3 (TACC3).

  2018cites this paper
• LAVH superior to TVH when concomitant salpingo-oophorectomy is intended in prolapse hysterectomy: a comparative cohort study

  2018cites this paper
• The association between BRCA 1 gene polymorphism and cancer risk : a meta-analysis

  2018cites this paper
• Which Environment Makes Cancer

  2018cites this paper
• Gynecological–endocrinological aspects in women carriers of BRCA1/2 gene mutations

  2018cites this paper
• Detection of BRCA1 gross rearrangements by droplet digital PCR

  2017cites this paper
• Update zur Retransplantation von Ovarialgewebe bei onkologischen Patienten

  2017cites this paper
• BRCA-Diagnostik an Ovarialkarzinomen

  2017cites this paper
• Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation

  2017cites this paper
• The matter of clinical sequencing for familial breast cancer: The route from Sanger to next generation

  2017cites this paper
• Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer

  2017cites this paper
• Is Ovarian Cancer Prevention Currently Still a recommendation of Our Grandparents?

  2017cites this paper
• novel mutation V 1736 D and analysis of SNP BRCA 1 in silico

  2017cites this paper
• Receptor tyrosine kinases and circulating tumor cells as new prognostic biomarkers in breast cancer with special focus on TNBC

  2017cites this paper
• BRCA1 novel mutation V1736D and in silico analysis of SNP Q356R in Sudanese patients with breast cancer

  2017cites this paper
• Germline Testing for Predisposition to Breast/Ovarian Cancer Should Only be Offered to Selected Patients with Epithelial Ovarian Cancer

  2017cites this paper
• Pratiques de dépistage du cancer des femmes non porteuses de mutations familiales des gènes BRCA1/2

  2017cites this paper
• Molecular Carcinogenesis in Gynecologic Neoplasias

  2017cites this paper
• Eligibility Criteria and Genetic Testing Results from a High-Risk Cohort for Hereditary Breast and Ovarian Cancer Syndrome in Southeastern Ontario.

  2016cites this paper
• Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review

  2016cites this paper
• Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation

  2016cites this paper
• Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology

  2016cites this paper
• Gr upSM Complementary and Alternative Medicine as Adjunct Therapy for the Ovarian Cancer Patients

  2016cites this paper
• Time to Diagnosis of Second Primary Cancers among Patients with Breast Cancer

  2016cites this paper
• Current-day precision oncology: from cancer prevention, screening, drug development, and treatment – have we fallen short of the promise?

  2016cites this paper
• Guidelines for complex genetic analysis of hereditary breast ovarian cancer syndrome in slovak population

  2015cites this paper
• The role of Rak in the regulation of stability and function of BRCA1

  2015cites this paper
• Common Hereditary Cancer Syndromes

  2015cites this paper
• Concepts of Anticancer Treatment and Pharmacogenomics in Cancer Treatments

  2015cites this paper
• The association between BRCA1 gene polymorphism and cancer risk: a meta-analysis

  2015cites this paper
• BRCA1 and BRCA2 mutations in Iranian breast cancer patients: A systematic review

  2015cites this paper
• Cost-Effectiveness of Combining MRI with Mammography for Breast Cancer Screening Among High-Risk Population in Ottawa

  2014cites this paper
• Hormone therapy in oophorectomized BRCA1/2 mutation carriers

  2014cites this paper
• Epidemiology, Risk Factors, Treatment, and Prevention of Breast Cancer Metastases

  2014cites this paper
• The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers.

  2014cites this paper
• Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers

  2014cites this paper
• Long-term follow-up after treatment of invasive and in situ breast cancer : aspects on second breast cancers HRQOL and lymphoedema

  2014cites this paper
• Management of Genetic Syndromes Predisposing to Gynecologic Cancers

  2013cites this paper
• Links between obesity, diabetes and ethnic disparities in breast cancer among Hispanic populations

  2013influential citation
• A Proposed Method for Mutational Disease Prediction Using Bioinformatics Tools and Back- propagation Algorithm

  2013cites this paper
• Novi primarni zloćudni tumori nakon dijagnoze raka dojke: međuodnos naslijeđa, rizičnih čimbenika i modaliteta liječenja [New primary malignancies after breast cancer diagnosis: interplay of genetics, risk factors and treatment modalities].

  2013cites this paper
• DNA Repair System: The Important Role in Cancers

  2013cites this paper
• [New primary malignancies after breast cancer diagnosis: interplay of genetics, risk factors and treatment modalities].

  2013cites this paper
• Double heterozygosity in the BRCA1 and BRCA2 genes in Italian family

  2013cites this paper
• Prognosis and predictive factors in human breast cancer during tumor progression

  2013cites this paper